Post-exposure prophylaxis with SA58 (anti-SARS-COV-2 monoclonal antibody) nasal spray for the prevention of symptomatic COVID-19 in healthy adult workers: a randomized, single-blind, placebo-controlled clinical study.


Journal

Emerging microbes & infections
ISSN: 2222-1751
Titre abrégé: Emerg Microbes Infect
Pays: United States
ID NLM: 101594885

Informations de publication

Date de publication:
Dec 2023
Historique:
medline: 29 5 2023
pubmed: 9 5 2023
entrez: 9 5 2023
Statut: ppublish

Résumé

Monoclonal antibodies (mAbs) and the post-exposure prophylaxis (PEP) with mAbs represent a very important public health strategy against coronavirus disease 2019 (COVID-19). This study has assessed a new Anti-SARS-COV-2 mAb (SA58) Nasal Spray for PEP against COVID-19 in healthy adults aged 18 years and older within three days of exposure to a SARS-CoV-2 infected individual. Recruited participants were randomized in a ratio of 3:1 to receive SA58 or placebo. Primary endpoints were laboratory-confirmed symptomatic COVID-19 within the study period. A total of 1222 participants were randomized and dosed (SA58,

Identifiants

pubmed: 37157134
doi: 10.1080/22221751.2023.2212806
pmc: PMC10215016
doi:

Substances chimiques

Nasal Sprays 0
Antibodies, Viral 0

Types de publication

Randomized Controlled Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2212806

Références

Nature. 2023 Feb;614(7948):521-529
pubmed: 36535326
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
China CDC Wkly. 2023 Mar 10;5(10):218-222
pubmed: 37006441
Cell Rep. 2022 Dec 20;41(12):111845
pubmed: 36493787
Int J Infect Dis. 2023 Jan;126:132-135
pubmed: 36511336
N Engl J Med. 2020 Jul 23;383(4):309-320
pubmed: 32640124
Nature. 2022 Feb;602(7898):657-663
pubmed: 35016194
BioDrugs. 2022 May;36(3):231-323
pubmed: 35476216
Science. 2020 Jul 24;369(6502):413-422
pubmed: 32532802
N Engl J Med. 1975 Nov 20;293(21):1055-9
pubmed: 1101065
N Engl J Med. 1969 May 29;280(22):1191-4
pubmed: 4181206
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748

Auteurs

Rui Song (R)

Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.

Gang Zeng (G)

Sinovac Biotech Co., Ltd., Beijing, People's Republic of China.

Jianxing Yu (J)

Sinovac Biotech Co., Ltd., Beijing, People's Republic of China.

Xing Meng (X)

Sinovac Biotech Co., Ltd., Beijing, People's Republic of China.

Xiaoyou Chen (X)

Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.

Jing Li (J)

Sinovac Life Sciences Co., Ltd., Beijing, People's Republic of China.

Xiaoliang Xie (X)

Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Changping Laboratory, Beijing, People's Republic of China.

Xiaojuan Lian (X)

Sinovac Life Sciences Co., Ltd., Beijing, People's Republic of China.

Zhiyun Zhang (Z)

Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.

Yunlong Cao (Y)

Biomedical Pioneering Innovation Center (BIOPIC), Peking University, Beijing, People's Republic of China.
Changping Laboratory, Beijing, People's Republic of China.

Weidong Yin (W)

Sinovac Biotech Co., Ltd., Beijing, People's Republic of China.

Ronghua Jin (R)

Beijing Ditan Hospital, Capital Medical University, Beijing, People's Republic of China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH